It makes every sense to do a R/S ..aprt from the $4/Nasdaq uplist target, the split will bring in major funding/Investors.
My guess is the split will happen close to FDA approval if phase 3 successful. So many positive possibilities for the company if they so the split. ...but again bad for shareholders ..well the ones who can't afford a lot of shares.